Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ONCY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsOncolytics Biotech appoints Stephen Glover to Board, promotes John McAdory to COO
Filed June 2, 2026 · Period ending June 2, 2026 · ~1 min read
Key Changes
-
medium
Stephen Glover appointed as ninth independent director. Glover brings 35+ years of biopharma leadership, currently CEO of ZyVersa Therapeutics and former Chairman of Ambrx through its $2B acquisition by Johnson & Johnson.
Item 5.02 verify on EDGAR → -
medium
John McAdory promoted from EVP Strategy and Operations to Chief Operating Officer effective June 1, 2026. McAdory previously led clinical operations at CG Oncology through Phase 3 and IPO. No additional compensation for the new role.
Item 5.02 verify on EDGAR → -
low
Glover granted option to purchase 96,000 shares at June 1 closing price, vesting in three equal annual installments of 32,000 shares contingent on continued board service.
Item 5.02 verify on EDGAR →
Summary
Oncolytics Biotech strengthened its leadership team with two key appointments effective June 1, 2026. The company promoted John McAdory to Chief Operating Officer from his previous role as EVP of Strategy and Operations, recognizing his operational expertise gained at CG Oncology. Simultaneously, the Board expanded to nine members by appointing Stephen Glover as an independent director.
Glover's extensive biopharma experience—including steering Ambrx through a $2 billion acquisition—adds strategic depth as Oncolytics advances its clinical programs. For retail investors, these moves signal operational maturation and governance strengthening at a critical stage for the biotech.
McAdory's promotion without additional compensation suggests internal confidence in existing talent, while Glover's track record in value-creating transactions could prove valuable if Oncolytics pursues partnerships or strategic alternatives. The standard equity grant to Glover (96,000 options vesting over three years) aligns his interests with shareholders. Watch for upcoming clinical trial updates or partnership announcements where this enhanced leadership team's impact may become evident.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
the Company issued a press release announcing the appointments of Stephen Glover to the Board
Stephen Glover has been appointed to the Board of Directors. Board appointments can signal strategic direction changes or governance strengthening, though no additional details about Glover's background or rationale are provided in the 8-K itself.
Added in current filing · verify on EDGAR →
the Company issued a press release announcing the appointments of Stephen Glover to the Board and John McAdory as Chief Operating Officer
John McAdory has been appointed as Chief Operating Officer. This is a key executive role responsible for day-to-day operations. The appointment may indicate operational expansion or restructuring, though no details about McAdory's background or compensation are disclosed in the 8-K body.
Event · Item 9.01 — Financial Statements and Exhibits
Oncolytics Biotech filed an 8-K attaching a press release dated June 2, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release issued by Oncolytics Biotech Inc., dated as of June 2, 2026.
The 8-K references an attached press release dated June 2, 2026 (Exhibit 99.1). The filing body provides no details about the content or subject matter of the press release, so the nature and materiality of the disclosed event cannot be determined from this 8-K alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify